SAN DIEGO , Aug. 19, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers...
Sionna Therapeutics Shares Lost Roughly 90% of Their Value After Phase 2a PreciSION CF Trial of SION-719 Failed to Achieve Its Key Sweat Chloride Endpoint.
The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of United States federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ:...
Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or...
Law Offices of Howard G. Smith announces an investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION ) investors concerning the Company’s...
The Law Offices of Frank R. Cruz announces an investigation of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION ) on behalf of investors concerning the...
Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and directors violated securities laws...
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna”...
Sionna Therapeutics shares lost roughly $40 per share after SION-719 Phase 2a readout, cutting the stock by about 90%. Levi & Korsinsky is investigating potential securities law violations on behalf of...
Sionna Therapeutics shares traded above $44 in July 2026; after the SION-719 Phase 2a readout, roughly 90% of that value was lost. SueWallSt notifies investors of a pending investigation into potential...